Adicet Bio, Inc. Comprehensive Income
Adicet Bio, Inc. (ACET) reported Comprehensive Income of -$21.43 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-05
- Adicet Bio, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$21.43M.
- Adicet Bio, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$20.38M.
- Adicet Bio, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$30.47M.
- Adicet Bio, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$26.76M.
- Adicet Bio, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$116.72M.
- Adicet Bio, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$117.11M.
- Adicet Bio, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$142.66M.
- Adicet Bio, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$69.79M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$21.43M 10-Q · filed 2026-08-05 | -$41.81M 10-Q · filed 2026-08-05 | -$72.28M derived: sum of 3 quarters · filed 2026-08-05 | -$99.04M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | -$20.38M 10-Q · filed 2026-05-13 | -$50.85M derived: sum of 2 quarters · filed 2026-05-13 | -$77.61M derived: sum of 3 quarters · filed 2026-05-13 | -$108.86M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | -$30.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$57.23M derived: sum of 2 quarters · filed 2026-03-12 | -$88.48M derived: sum of 3 quarters · filed 2026-08-05 | -$116.72M 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | -$26.76M 10-Q · filed 2025-11-05 | -$58.01M derived: sum of 2 quarters · filed 2026-08-05 | -$86.25M 10-Q · filed 2025-11-05 | -$115.08M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | -$31.25M 10-Q · filed 2026-08-05 | -$59.49M 10-Q · filed 2026-08-05 | -$88.32M derived: sum of 3 quarters · filed 2026-08-05 | -$118.68M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | -$28.24M 10-Q · filed 2026-05-13 | -$57.07M derived: sum of 2 quarters · filed 2026-05-13 | -$87.43M derived: sum of 3 quarters · filed 2026-05-13 | -$117.33M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | -$28.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$59.19M derived: sum of 2 quarters · filed 2026-03-12 | -$89.09M derived: sum of 3 quarters · filed 2026-03-12 | -$117.11M 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | -$30.36M 10-Q · filed 2025-11-05 | -$60.26M derived: sum of 2 quarters · filed 2025-11-05 | -$88.27M 10-Q · filed 2025-11-05 | -$117.76M derived: sum of 4 quarters · filed 2025-11-05 | ||||
| 2024-06-30 | -$29.90M 10-Q · filed 2025-08-07 | -$57.92M 10-Q · filed 2025-08-07 | -$87.41M derived: sum of 3 quarters · filed 2025-08-07 | -$137.29M derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | -$28.02M 10-Q · filed 2025-05-06 | -$57.51M derived: sum of 2 quarters · filed 2025-05-06 | -$107.39M derived: sum of 3 quarters · filed 2025-05-06 | |||||
| 2023-12-31 | -$29.49M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$79.37M derived: sum of 2 quarters · filed 2025-03-06 | -$142.66M 10-K · filed 2025-03-06 | |||||
| 2023-09-30 | -$49.88M 10-Q · filed 2024-11-06 | -$113.17M 10-Q · filed 2024-11-06 | ||||||
| 2022-12-31 | -$29.88M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$51.87M derived: sum of 2 quarters · filed 2023-03-15 | -$74.41M derived: sum of 3 quarters · filed 2023-03-15 | -$69.79M 10-K · filed 2023-03-15 | ||||
| 2022-09-30 | -$22.00M 10-Q · filed 2022-11-08 | -$44.53M derived: sum of 2 quarters · filed 2022-11-08 | -$39.91M 10-Q · filed 2022-11-08 | -$55.73M derived: sum of 4 quarters · filed 2023-03-15 | ||||
| 2022-06-30 | -$22.54M 10-Q · filed 2022-08-10 | -$17.92M 10-Q · filed 2022-08-10 | -$33.73M derived: sum of 3 quarters · filed 2023-03-15 | -$47.75M derived: sum of 4 quarters · filed 2023-03-15 | ||||
| 2022-03-31 | $4.62M 10-Q · filed 2022-05-12 | -$11.20M derived: sum of 2 quarters · filed 2023-03-15 | -$25.21M derived: sum of 3 quarters · filed 2023-03-15 | -$36.06M derived: sum of 4 quarters · filed 2023-03-15 | ||||
| 2021-12-31 | -$15.81M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$29.83M derived: sum of 2 quarters · filed 2023-03-15 | -$40.68M derived: sum of 3 quarters · filed 2023-03-15 | -$62.02M 10-K · filed 2023-03-15 | ||||
| 2021-09-30 | -$14.01M 10-Q · filed 2022-11-08 | -$24.87M derived: sum of 2 quarters · filed 2022-11-08 | -$46.21M 10-Q · filed 2022-11-08 | -$55.23M derived: sum of 4 quarters · filed 2022-11-08 | ||||
| 2021-06-30 | -$10.86M 10-Q · filed 2022-08-10 | -$32.20M 10-Q · filed 2022-08-10 | -$41.21M derived: sum of 3 quarters · filed 2022-08-10 | -$56.11M derived: sum of 4 quarters · filed 2022-08-10 | ||||
| 2021-03-31 | -$21.34M 10-Q · filed 2022-05-12 | -$30.36M derived: sum of 2 quarters · filed 2022-05-12 | -$45.25M derived: sum of 3 quarters · filed 2022-05-12 | -$53.52M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | -$9.02M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$23.91M derived: sum of 2 quarters · filed 2022-03-15 | -$32.18M derived: sum of 3 quarters · filed 2022-03-15 | -$36.68M 10-K · filed 2022-03-15 | ||||
| 2020-09-30 | -$14.89M 10-Q · filed 2021-11-10 | -$23.16M derived: sum of 2 quarters · filed 2021-11-10 | -$27.66M 10-Q · filed 2021-11-10 | -$34.21M derived: sum of 4 quarters · filed 2021-11-10 | ||||
| 2020-06-30 | -$8.27M 10-Q · filed 2021-08-12 | -$5.63M 10-Q · filed 2020-07-30 | -$12.77M 10-Q · filed 2021-08-12 | -$12.69M 10-Q · filed 2020-07-30 | -$19.32M derived: sum of 3 quarters · filed 2021-08-12 | -$34.10M derived: sum of 4 quarters · filed 2021-08-12 | ||
| 2020-03-31 | -$4.50M 10-Q · filed 2021-05-17 | -$7.05M 10-Q · filed 2020-05-07 | -$11.05M derived: sum of 2 quarters · filed 2021-05-17 | -$25.84M derived: sum of 3 quarters · filed 2021-05-17 | -$44.03M derived: sum of 4 quarters · filed 2021-05-17 | |||
| 2019-12-31 | -$6.55M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | -$21.34M derived: sum of 2 quarters · filed 2021-03-12 | -$39.53M derived: sum of 3 quarters · filed 2021-03-12 | -$28.10M 10-K · filed 2021-03-12 | -$82.65M 10-K · filed 2020-03-12 | |||
| 2019-09-30 | -$14.78M 10-Q · filed 2020-11-05 | -$24.51M 10-Q · filed 2019-11-05 | -$32.98M derived: sum of 2 quarters · filed 2020-11-05 | -$21.55M 10-Q · filed 2020-11-05 | -$53.70M 10-Q · filed 2019-11-05 | -$21.35M derived: sum of 4 quarters · filed 2021-03-12 | ||
| 2019-06-30 | -$18.19M 10-Q · filed 2020-07-30 | -$29.19M 10-Q · filed 2020-07-30 | -$6.57M derived: sum of 3 quarters · filed 2021-03-12 | -$15.02M derived: sum of 4 quarters · filed 2021-03-12 | ||||
| 2019-03-31 | -$11.00M 10-Q · filed 2020-05-07 | $11.63M derived: sum of 2 quarters · filed 2021-03-12 | $3.17M derived: sum of 3 quarters · filed 2021-03-12 | -$10.45M derived: sum of 4 quarters · filed 2021-03-12 | ||||
| 2018-12-31 | $22.62M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $14.17M derived: sum of 2 quarters · filed 2021-03-12 | $547.00K derived: sum of 3 quarters · filed 2021-03-12 | -$9.31M 10-K · filed 2021-03-12 | -$37.66M 10-K · filed 2019-03-18 | |||
| 2018-09-30 | -$8.45M 10-Q · filed 2019-11-05 | -$22.07M derived: sum of 2 quarters · filed 2019-11-05 | -$31.93M 10-Q · filed 2019-11-05 | -$54.99M derived: sum of 4 quarters · filed 2020-03-12 | ||||
| 2018-06-30 | -$13.62M 10-Q · filed 2019-08-14 | -$23.48M 10-Q · filed 2019-08-14 | -$46.53M derived: sum of 3 quarters · filed 2020-03-12 | -$49.84M derived: sum of 4 quarters · filed 2020-03-12 | ||||
| 2018-03-31 | -$9.86M 10-Q · filed 2019-05-15 | -$32.91M derived: sum of 2 quarters · filed 2020-03-12 | -$36.22M derived: sum of 3 quarters · filed 2020-03-12 | -$40.28M derived: sum of 4 quarters · filed 2020-03-12 | ||||
| 2017-12-31 | -$23.05M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$26.36M derived: sum of 2 quarters · filed 2020-03-12 | -$30.42M derived: sum of 3 quarters · filed 2020-03-12 | -$33.78M 10-K · filed 2020-03-12 | ||||
| 2017-09-30 | -$3.31M 10-Q · filed 2018-11-13 | -$7.37M derived: sum of 2 quarters · filed 2018-11-13 | -$10.72M 10-Q · filed 2018-11-13 | |||||
| 2017-06-30 | -$4.06M 10-Q · filed 2018-08-09 | -$7.41M 10-Q · filed 2018-08-09 | ||||||
| 2016-12-31 | -$1.00K 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |